Drug-disease interactions in Swedish senior primary care patients were dominated by non-steroid anti-inflammatory drugs and hypertension - a population-based registry study by Schmidt-Mende, Katharina et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Drug-disease interactions in Swedish senior primary care patients were dominated by
non-steroid anti-inflammatory drugs and hypertension - a population-based registry
study
Schmidt-Mende, Katharina; Andersen, Morten; Wettermark, Bjorn; Hasselstrom, Jan
Published in:
Scandinavian Journal of Primary Health Care. Supplement
DOI:
10.1080/02813432.2020.1794396
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Schmidt-Mende, K., Andersen, M., Wettermark, B., & Hasselstrom, J. (2020). Drug-disease interactions in
Swedish senior primary care patients were dominated by non-steroid anti-inflammatory drugs and hypertension -
a population-based registry study. Scandinavian Journal of Primary Health Care. Supplement, 38(3), 330-339.
https://doi.org/10.1080/02813432.2020.1794396
Download date: 09. Oct. 2020
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ipri20
Scandinavian Journal of Primary Health Care
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ipri20
Drug–disease interactions in Swedish senior
primary care patients were dominated by non-
steroid anti-inflammatory drugs and hypertension
– a population-based registry study
Katharina Schmidt-Mende , Morten Andersen , Björn Wettermark & Jan
Hasselström
To cite this article: Katharina Schmidt-Mende , Morten Andersen , Björn Wettermark &
Jan Hasselström (2020) Drug–disease interactions in Swedish senior primary care patients
were dominated by non-steroid anti-inflammatory drugs and hypertension – a population-
based registry study, Scandinavian Journal of Primary Health Care, 38:3, 330-339, DOI:
10.1080/02813432.2020.1794396
To link to this article:  https://doi.org/10.1080/02813432.2020.1794396
© 2020 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
View supplementary material 
Published online: 29 Jul 2020. Submit your article to this journal 
Article views: 203 View related articles 
View Crossmark data
RESEARCH ARTICLE
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a population-based registry study
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aAcademic Primary Health Care Centre, Region Stockholm and Division of Family Medicine, Department of Neurobiology, Care
Sciences and Society, Karolinska Institute, Sweden; bDepartment of Drug Design and Pharmacology, Faculty of Health and Medical
Sciences, University of Copenhagen, Copenhagen, Denmark; cDepartment of Pharmacy, Disciplinary Domain of Medicine and
Pharmacy, Uppsala University, Uppsala, Sweden
ABSTRACT
Objective: Drug–disease interactions (DDSIs) are present when a drug prescribed for one dis-
ease worsens a concomitant disease. The prevalence of DDSIs in older patients in primary care
is largely unknown, as well as to what extent physicians individualize drug prescribing in rela-
tion to concomitant diseases. We therefore analysed the prevalence of DDSIs in older patients
in primary care and explored to what extent physicians take possible DDSIs into account when
prescribing.
Design and Setting: Cross-sectional population-based register study in primary care in Region
Stockholm, Sweden. Thirty-one DDSIs derived from Irish STOPP-START-Criteria were assessed. We
derived data from a regional administrative healthcare database including information on all
healthcare consultations and dispensed prescription drugs in the region. Data on demography,
diagnoses, drug dispensations and healthcare consumption were extracted. Drugs were assessed
during 2016.
Subjects: A total of 336,295 patients aged 65 registered with one of the 206 primary care
practices in Region Stockholm.
Main outcome measures: Prevalence and prevalence differences for DDSIs.
Results: In 10.8% of older patients, at least one DDSI was observed. Non-steroidal anti-inflam-
matory drugs (NSAIDs) were implicated in more than 75% of cases. The most common DDSI
was NSAID/hypertension (8.1%), followed by NSAID/cardiovascular disease and loop diuretics/
urinary incontinence (both 0.7%). The use of NSAIDs among patients with heart failure or
impaired renal function was 15% lower than among patients without these diseases.
Conclusion: DDSIs were present in every tenth older patient in primary care. Patients with car-
diovascular disease receive NSAIDs to a lower extent, possibly indicating physician awareness
of DDSI.
KEY POINTS
 Evidence on the prevalence of drug–disease interactions in older patients in primary care is
sparse despite their potential to cause harm.
 In this study, we found that every 10th older patient attending primary care had at least one
drug–disease interaction.
 Interactions with NSAIDs were far more common than interactions with other drugs.
 The use of NSAIDs among patients with heart failure or impaired renal function was 15%
lower than among patients without these diseases.
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Introduction
Older people are a growing population group and
WHO foresees every fourth person to be 65 or older
by 2050 [1]. Parallel with age, the number of diseases
increase. Multimorbidity, defined as the presence of
two or more chronic diseases, is present in more than
50% of older patients in a primary care setting [2,3].
Multimorbidity patients are at risk to receive drugs
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that treat one condition (¼indication for drug treat-
ment) but at the same time worsen a comorbidity
(¼interacting disease) [4]. One example of such a
drug–disease interaction (DDSI) is the use of non-ster-
oidal anti-inflammatory drugs (NSAIDs) against osteoarth-
ritic pain in a patient who has heart failure.
There is no universally applicable list of interacting
drugs and diseases. Most criteria for potentially
inappropriate prescribing do not include DDSIs as a
specific category [5].
The assessment of the frequency and nature of
DDSIs in a primary care setting is important as they
may have deleterious effects for older patients [6].
Primary care has a key role in the care of multimorbid
older patients [7] and the majority of drugs to this
patient group are prescribed by primary care physi-
cians [8]. There is limited knowledge on the preva-
lence and risk factors for DDSIs in older patients
attending primary care. We are aware of one system-
atic review from 2013 including eight studies [9] as
well as five studies published since 2013 [10–14] on
the prevalence of DDSIs. Ten of these 13 studies were
conducted in the United States, one in China [14], and
two in Europe [12,13]. Only one study was performed
in European primary care [13]. As definitions of DDSIs
and settings vary, large differences in prevalence are
found, ranging from 3% [15] to 50% [11]. Studies in
nursing home residents [11] report higher prevalence
(50%) than studies in community-dwelling older peo-
ple (15–20%) [10,12].
Our aim was to explore the prevalence of DDSIs in
older patients attending primary care in a European
capital (Stockholm, Sweden). We hypothesised that
the prevalence of interacting drugs is lower in patients
with interacting disease than in patients without.
Material and methods
Study design and setting
This was a retrospective, cross-sectional population-
based register study. All patients aged 65 on 1
January 2016, registered with any of the totally 206
primary healthcare practices in the Region of
Stockholm, Sweden, in December 2015, alive 31
December 2016, and resident during the entire year
2016 were included. Only 1% of the community-liv-
ing population in Stockholm aged 65 was not regis-
tered with a primary care practice and thus not
included in the analyses. Of note, nursing home resi-
dents (n 15.000 corresponding to 4% of the popu-
lation aged  65 in 2016 in Region Stockholm) were
not analyzed as they receive medical care from geria-
tricians instead of primary care.
Swedish primary care system
In Sweden, primary healthcare is provided by public
and privately run primary healthcare practices that
operate under contracts with the county council, the
public payer for healthcare for all citizens in a defined
geographic area [16]. Patients may seek specialist care
without a referral from a GP or other primary health
care professional, as primary care does not have a
gatekeeper function [17]. However, when people
experience a health problem, their first point of con-
tact is typically a GP or nurse at a primary care prac-
tice. People aged 65 years and older in Region
Stockholm meet their GP a mean of 3.8 times a year.
All residents have access to health care for low patient
fees, and for people over the age of 85 there is no
patient fee at all. Health expenditures as well as medi-
cine costs are covered by the national insurance sys-
tem. With exception for some private caregivers, the
majority (>90%) of prescribing physicians in Region
Stockholm have access to the patients entire drug list
as they share the health record. Dispensing pharma-
cies have access to the entire list of prescribed drugs
independent of the prescriber.
Data source and variables
Data were extracted from Stockholm regional health-
care data warehouse (Swedish VAL) [16,17], which is a
database that contains all data on all health care con-
sumption, diagnoses, dispensed drug prescriptions,
migration, and deaths for all 2.4 million inhabitants of
Region Stockholm. Data recorded in VAL is the basis
for reimbursement and follow-up monitoring of sup-
plied healthcare for all citizens in the region. ICD-10
diagnoses recorded during hospital stays are the same
as for the National Patient Register [18]. With some
exceptions (for example, cancer), diagnoses in the
National Patient Register have a positive predictive
value of 85% to 95%, which implies high validity [21].
VAL even includes diagnoses recorded at primary care
consultations. Of note, diagnoses given by some pri-
vate caregivers who do not have contract with the
public payer as well as diagnoses from caregivers out-
side Region Stockholm are not recorded in VAL. Still,
as the majority of patients consulting those caregivers
even consult primary care and hospitals in Region
Stockholm we estimate the risk for missing data to be
low (<5%). Information on at least one diagnosis was
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available for more than 95% of primary care consulta-
tions, for 99% of specialist ambulatory consultations,
and for 99% of hospitalizations. Dispensed prescription
drugs in VAL are derived from the Swedish prescribed
Drug Register [19]. The validity of this register is high
[20], more than 99% of prescriptions are registered
with unique identifiers. Of note, drugs given during
hospital stays and over-the-counter drugs are not
included. We extracted information on sex, age, migra-
tion, death, ICD-10 diagnoses at consultation in pri-
mary care, specialist ambulatory care and
hospitalization, and dispensed prescription drugs
regardless of prescriber category.
Definition of drug–disease interactions
DDSIs were extracted from the STOPP-section of Irish
STOPP-START criteria version 2 [5,21]. However, they
do not contain a separate list of DDSIs. Therefore, we
selected 29 from a total of 80 STOPP-indicators if they
werea DDSI according to the definition provided by
Pugh et al. [4] (Appendix Table 1). Some of the
STOPP-indicators contained not only one but several
(2 to 5) DDSIs, for example D1 (‘tricyclic antidepres-
sants with dementia, narrow angle glaucoma, cardiac
conduction abnormalities, prostatism, or prior history
of urinary retention (risk of worsening these condi-
tions)’). The final list comprised 31 DDSIs (Table 1).
Patients were considered to have a DDSI when they
had an ICD-10-code for the interacting disease (Table
1) and had purchased at least one prescription of the
interacting drug(s) in 2016. We analysed drugs that
had been dispensed after a prescription by a physician
working in primary care, specialist ambulatory or
inpatient care in Sweden, but not over-the-counter
drugs or drugs given during hospital stay. The drugs
were classified in accordance with the Anatomical
Therapeutic and Chemical (ATC) classification system
[22]. Dermatologicals (ATC group ‘D’) were excluded
from analyses.
Definition of diseases
Diseases were assessed based on ICD-10 codes regis-
tered in primary care, specialist ambulatory or
inpatient care.
We differentiated between (1) chronic diseases that
described the study population, identified by one code
2012–2016: cardiovascular disease (hypertension, coron-
ary heart disease, heart failure, peripheral arterial disease,
atrial fibrillation), cerebrovascular disease (stroke, transi-
ent ischemic attack), cancer, chronic respiratory disease
(chronic obstructive pulmonary disease, asthma), dia-
betes; (2) interacting diseases (diseases that are poten-
tially worsened by the interacting drug). Depending on
the severity and chronicity of disease, we applied three
different time frames (Figure 1): (a) For chronic diseases:
one code 2012–2016; (b) For severe but less chronic
disease:  one code 2015–2016; (c) For less severe dis-
ease: one code 2015 and 2016; and (3) a pain-diagno-
sis in order to identify patients with possibly
contraindicated NSAIDs: osteoarthritis (M15-19) or rheu-
matologic disease (M05-14) once 2012–2016 or the
same chronic pain diagnoses (pain in shoulder, leg, foot,
back, fibromyalgia M75-77, M79, M53, M54, R52 without
R52.0, migraine G43, headache G44, R51) once 2015
and once 2016.
Other variables
Demographic variables included sex and age on 1
January 2016, as well as death and migration in or out
of Region Stockholm in 2016. Regarding healthcare
consumption, the following variables were assessed:
registration with a primary care practice in December
2015, physician visits in primary health care, and visits
at emergency departments at one of the total of
seven emergency hospitals in Region Stockholm.
In order to calculate the total number of drugs pre-
scribed to a patient we assessed the number of dis-
pensations during a 4-month period (1 January 2016
to 30 April 2016). The choice of a 4-month interval is
due to Swedish reimbursement regulations: Each pre-
scription generally mandate a time window of three
months between two dispensations [23].
Statistics
We calculated prevalence and two-tailed 95% binomial
confidence intervals as well as prevalence differences and
two-tailed 95% confidence intervals for diseases and
DDSIs. For numerical values we present relevant descrip-
tive statistics, mean and standard deviation (SD) or
median and interquartile range (IQR).
Data extraction was performed with SAS Enterprise
Guide version 7.1, and statistical analyses were under-
taken in STATA version 14.
Results
Study population
After the exclusion of 16,648 people (death and/or
move), the study population consisted of 336,295
patients with a mean age of 74.3 years (SD 7.4). There
were more women than men (55 vs. 45%) (Table 2).
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Cardiovascular diseases were the most prevalent
disease group. Individuals met their GP in median 4
times a year. Each patient was dispensed a median of
four (IQR 2;7) prescription drugs. Of note, 16% had no
drug treatment at all, and 12% had 10 drugs.
Prevalence of drug–disease interactions
In 10.8% of patients, at least one DDSI was seen. Nine
per cent (n¼ 37,773) of the study population had one
DDSI, 1.4% had two DDSIs, and <0.4% had three or
more DDSIs.
Figure 2(a) shows the 20 most common DDSIs.
One DDSI was far more common than all others:
use of NSAIDs in patients with hypertension. It was
observed in 8.1% of total study population, thus
explaining 75% of the total prevalence of DDSIs.
Moreover, NSAIDs were included in five out of the
20 most commonly observed DDSIs shown in Figure
2(a) (red bars). It is important to note that there
was a long tail of 11 DDSIs that were very uncom-
mon and prescribed each to less than 100 patients
(Appendix Table 2).
Table 1. 31 drug–disease interactions that were assessed for their prevalence.
STOPP-
criteria Interacting drug ATC Interacting disease
ICD-10 and
assessment period
B8 Thiazide diuretic C03A gout M10 once 2012–2016
B9 Loop diuretic C03CA urinary incontinence N39.3,
N39.4 once 2012–2016
C2 (Low-dose) acetylsalicylic acid
without proton-
pump-inhibitor
B01AC06, A02BC
acetylsalicylic acid once 2016 but
no proton-pump-inhibitor 2016
peptic ulcer disease K25-28 once 2015–2016
C2 Acetylsalicylic acid without
proton-pump-inhibitor
N02BA, A02BC
acetylsalicylic acid once 2016 but
no proton-pump-inhibitor 2016
peptic ulcer disease K25-28 once 2015–2016
D1 Tricyclic antidepressants N06AA dementia F00-03, G30 once 2012–2016
D1 Tricyclic antidepressants N06AA narrow angle glaucoma H40.2 once 2012–2016
D1 Tricyclic antidepressants N06AA benign prostate hyperplasia N40 once 2012–2016
D3 Neuroleptics with moderate-
marked antimuscarinic/
anticholinergic effects
N05AH02, N05AF01, N05AB02, N05AF05 benign prostate hyperplasia N40 once 2012–2016
D6 Antipsychotics (i.e. other than
quetiapine or clozapine)
N05AA, N05AB, N05AD, N05AE, N05AF M Parkinson G20 once 2012–2016
D8 Anticholinergic drugs A03AB, A03BA, A03BB,
A04AD, C01BA,N02AG,
N04A, N05AA, N05AF03, N05AH02,
N05BB01, N06AA, R06AA02, R06AB,
R06AD, R06AX02
dementia F00-03, G30 once 2012–2016
E4 NSAIDs M01A without M01AX05 impaired renal function N18.3-18.5, N18.9
N19.9 once 2012–2016
F1 Prochlorperazine or
metoclopramide
A03FA01 M Parkinson G20 once 2012–2016
F3 Anticholinergic/
antimuscarinic drugs
A03AB, A03BA, A03BB,
A04AD, C01BA,N02AG,
N04A, N05AA, N05AF03, N05AH02,
N05BB01, N06AA, R06AA02, R06AB,
R06AD, R06AX02, G04BD
constipation K59 once 2015
AND once 2016
F3 Oral iron B03A constipation K59 once 2015
AND once 2016
F3 Opioids N02A constipation K59 once 2015
AND once 2016
F3 Verapamil C08DA01 constipation K59 once 2015
AND once 2016
F3 Aluminium antacids A02AD01 constipation K59 once 2015
AND once 2016
G3 Anti-muscarinic bronchodilators R03BB01, R03BB04 narrow angle glaucoma H40.2 once 2012–2016
G3 Anti-muscarinic bronchodilators R03BB01, R03BB04 benign prostate hyperplasia N40 once 2012–2016
G4 Benzodiazepines N05BA, N05BA01, N05CD02, N05CD03 obstructive sleep apnea G47.3 once 2012–2016
H1 Non-COX-2 selective NSAIDs
without proton-pump-
inhibitor or H2-blockers
M01AB, M01AC, M01AE, M01AX01 peptic ulcer disease K25-28 once 2015–2016
H2 NSAIDs M01A without M01AX05 hypertension I10-15 once 2012–2016
H2 NSAIDs M01A without M01AX05 heart failure I50 once 2012–2016
H7 COX-2 selective NSAIDs M01AH, M01AB05 concurrent cardiovascular disease (coronary heart
disease, peripheral arterial disease,
cerebrovascular disease, TIA)
I20-25, I70-79, I63.0-I63.9, I61.0-
I61.9, I64, G45.9,
Z86.6A once 2012–2016
H9 Oral bisphosphonates M05BA, M05BB history of upper gastrointestinal disease i.e.
dysphagia, oesophagitis, gastritis, duodenitis,
or peptic ulcer disease, or upper
gastrointestinal bleeding
K20-K29, K31
once 2015 2016
I1 Antimuscarinic drugs G04BD dementia F00-03, G30 once 2012–2016
I1 Antimuscarinic drugs G04BD narrow-angle glaucoma H40.2 once 2012–2016
I1 Antimuscarinic drugs G04BD benign prostate hyperplasia N40 once 2012–2016
J2 Thiazolidenediones A10BG heart failure I50 once 2012–2016
J4 Oestrogens G03C (only oral) breast cancer C50 once 2012–2016
J4 Oestrogens G03C (only oral) venous thromboembolism I26, I82 once 2012–2016
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There were a total of 31 DDSIs in relation to 17
interacting diseases. The most common interacting
disease was hypertension (Figure 2(b) and Appendix
Table 3).
Several interacting diseases such as constipation
and benign prostate hyperplasia were potentially
worsened by several interacting drugs. The prevalence
of the interacting drug in patients with an interacting
disease was at its most 50% (drugs interacting with
constipation). Of note, this high percentage was
mainly due to opioids (30%) (Appendix Table 3).
Prevalence of NSAIDs in patients with or without
interacting disease
NSAIDs were far more common than all other interact-
ing drugs, and were implicated in five of the 20 most
prevalent DDSIs. The prevalence of NSAID in two dif-
ferent patient groups having a chronic pain diagnosis
was compared (Appendix Figure 1). We found that
NSAID use was less prevalent in patients with an inter-
acting disease/disease group compared to patients
without (Figure 3 and Appendix Table 4). For example,
Figure 1. Time frames for assessment of diseases.
GERD: Gastroesophageal reflux disease
Table 2. Basic characteristics of study population (n¼ 336,295).
Total
%
(if not indicated otherwise)
Age in years 65–74 59.9
75–84 28.6
85 and older 11.6
Morbiditya Cardiovascular diseaseb 59.4
Cancer 17.8
Diabetes 15.4
Chronic respiratory diseasesc 12.2
Cerebrovascular diseased 7.4
Healthcare consumption Median nr of visits with GP (IQR) 4 (2;9)
Median nr of emergency department visits (IQR) 0 (0;1)
a1 January 2012 to 31 December 2016.
bHypertension, coronary heart disease, heart failure, atrial fibrillation, peripheral arterial disease.
cChronic obstructive pulmonary disease, asthma.
dStroke, transient ischemic attack.
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within the group of patients with chronic pain, those
with heart failure had a 15% lower risk of NSAID use
compared to patients without heart failure (13 vs.
28%). The corresponding numbers for impaired renal
function were 12 vs. 27%, for concurrent cardiovascu-
lar disease 7 vs. 11%, for peptic ulcer disease 13 vs.
17%, and for hypertension 25 vs. 28%.
Discussion
Summary
In a total primary care population in Region
Stockholm, 10.8% of older patients were found to
have at least one DDSI. The most common interacting
drugs were NSAIDs which were implicated in five
Figure 2. (a,b) Number of patients with drug-disease interaction in the total population (2a) and grouped by interacting disease
(2 b) (total population n¼ 336,295). For corresponding numbers: see appendix, Tables 2 and 3. (a) Prevalence of the 20 most com-
monly seen drug-disease interactions.
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DDSIs and accounted for more than 80% of potentially
inappropriate prescribing. At most 50% of patients
with an interacting disease were treated with an inter-
acting drug. Among patients with pain diagnosis,
NSAIDs were prescribed to a lower extent to those
with interacting disease compared to those without
interacting disease.
Strengths and limitations
To our knowledge, this is the largest population-based
analysis on the prevalence of DDSIs in older patients
attending primary care. DDSIs were selected from and
defined in relation to STOPP-START criteria [5]. These
criteria as a whole have high clinical relevance and
predictive ability [21]. As the area of DDSI suffers from
incomplete definitions both as regards which interac-
tions to use (for example, STOPP-START criteria [5],
Beers criteria [24]) as well as which time frames to use
when choosing diagnoses and drug use it may be
hard to judge whether our findings are due to the cri-
teria used or reflect a true Swedish prescribing situ-
ation. We have described the selection process in
detail in the appendix, making it possible to critically
evaluate the basis for our choices. The reader should
also be aware that the definition we chose for DDSIs
is not a fully validated one, and there may be more
DDSIs than the ones included in the STOPP-START cri-
teria. For example, the use of cortisone in patients
with diabetes is not included as STOPP-indicator. It is
therefore likely that the true prevalence of DDSIs is
higher than we reported.
Register data are easily collected and allow to ana-
lyze large populations without recall or selection bias.
There are however possible bias stemming from the
validity of diagnoses. Diagnoses drawn from hospital-
based registers usually have high validity [18] as have
common diagnoses like hypertension, diabetes [25]
and heart failure [26] in primary care. Still, the validity
of diagnoses coded in primary care has not been suffi-
ciently analysed. In patients with renal failure, underre-
porting of ICD-10 diagnoses is a bigger problem than
overreporting [27]: 25% of patients aged 65 and older
where a creatinine had been taken had renal impair-
ment stage 3 or 4, whereas only 5% had an ICD-10
code for renal impairment. We therefore think that the
prevalence of interacting diseases and thus the true
prevalence of DDSIs is higher than the one we
reported due to insufficient coding of ICD-10 diagno-
ses. More uncommon diagnoses such as glaucoma
though, have been less studied.
Although the validity of the prescribed drug regis-
ter from which we collected our dispensation data is
high [19], information on intake of drugs rather than
dispensation is a limitation. Five DDSIs could moreover
not be assessed due to lack of clinical data, such as
STOPP-indicator I1 (antimuscarinic drugs for overactive
bladder syndrome with concurrent chronic cognitive
impairment). In relation to the interaction between
opioids and constipation, it would have been import-
ant to check even for parallel dispensation of laxatives
which we did not do. However, Christensen et al. [28]
state that 48% of patients with opioid-induced consti-
pation did not benefit from laxatives which argues in
favour of our way of assessment.
Figure 3. Prevalence differences and 95% confidence intervals of NSAID use in patients with a pain diagnosis and with/without
an interacting disease.
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A major challenge was the definition of time frames
under which diseases should be coded. We differenti-
ated between chronic diseases coded once during
5 years such as heart failure, “less chronic” diseases
such as gastrointestinal bleeding coded once during
2 years, and ‘less severe’ diseases such as constipation
coded twice during 2 years. This definition relied on
unpublished sensitivity analyses and our clinical
experience and may thus be subject to discussion.
However, we think that neither of these limitations
implied a substantial over- or underreporting of the
true prevalence of DDSIs. Of note, we analysed only
prescription drugs. As NSAIDs are available as over-
the-counter drugs it is possible that the true preva-
lence of DDSIs is higher than described in our study.
Due to the cross-sectional design, it is not sure that
the interacting disease preceded the dispensation of
the interacting drug. Even an adverse drug reaction
rather than a DDSI is possible: the use of NSAIDs lead
to a peptic ulcer. This possibility cannot be ruled out,
although it is unlikely; drug use was assessed during
2016, whereas interacting diseases were measured
during 2012–2016 or 2015–2016. It is thus highly
probable that the interacting disease was present
before drug dispensation. A prospective approach,
though more complicated, may give a clearer answer
to those questions.
Comparison with existing literature
We are not aware of a study that describes the preva-
lence of DDSIs in a European primary care setting
using STOPP-START criteria version 2 [5]. A study from
German primary care describes a prevalence of 10.4%
using Beers Criteria [13] based on a patient group
with predefined interacting diseases. This is in contrast
to our study as we included all older patients in pri-
mary care. Regarding the prevalence of single DDSIs,
Dreischulte et al. [29] found that 2.1% of older
patients with heart failure in Scottish primary care
used NSAIDs during a period of 8weeks preceding the
assessment date, whereas the corresponding percent-
age in our study was 7.9% (Appendix Table 4). A pos-
sible explanation of the threefold higher prevalence in
our study is that we assessed NSAID use during one
year, making it difficult to compare the findings. In
general, it is important to note that DDSIs are less
common than other types of potentially inappropriate
prescribing such as drug-drug interactions [30] or
excessive dosing in relation to impaired renal func-
tion [27].
Hanlon et al. analysed the prevalence of DDSIs by
Beers Criteria in older adults living in a US community
setting [12]. In keeping with findings in our study,
NSAIDs were most frequently involved. The most
prevalent DDSI with NSAID in Hanlons study was
‘peptic ulcer disease and aspirin/NSAIDs without gas-
troprotection’. However, Beers Criteria do not define
hypertension/NSAID as a DDSI. The predominance of
NSAIDs in our study relies mainly on the interaction
between hypertension and NSAIDs. The clinical rele-
vance of this DDSI may however be questioned: pri-
mary care patients with hypertension and regular
NSAID use reached target blood pressure to the same
extent as patients without NSAIDs [31]. This highlights
the importance of prospective studies analysing to
what extent DDSIs actually cause harm, as well as of
regular updates of criteria of potentially inappropriate
prescribing.
Implications for research and/or practice
Physicians experience that potentially inappropriate
prescribing is complex [32]. However, we found that
only a limited number of drugs is implicated in the
context of DDSIs. We analysed 31 DDSIs and found
that NSAIDs were implicated in more than 80% of
cases equal to five DDSIs. In view of the time con-
straints physicians in primary care face this finding
may help to target medication reviews, and at the
same time to increase their quality. Regarding DDSIs,
GPs prescribing habits may successfully be improved if
they focus on the inappropriate use of NSAIDs.
An interesting finding was that older patients with
chronic pain and heart failure were prescribed NSAIDs
to a significantly lower extent than those with chronic
pain but without heart failure. A possible explanation
may be that physicians are aware of DDSIs to a certain
extent, and prescribe cautiously in older patients with
multimorbidity. However, although we found up to
15% lower risk of NSAIDs in conjunction with heart
failure, there is room for improvement of prescribing,
as there were still 1,920 older patients with pain and
heart failure who were dispensed NSAIDs at
least once.
It is possible that this finding reflects physicians
deliberate balancing of benefit against harm [33]
rather than a more black or white concept of
‘potentially inappropriate prescribing’. Physician and
patient may for instance have decided that the short-
term use of NSAIDs against severe pain outweighs the
possible aggravation of heart failure. Qualitative stud-
ies should elucidate to what extent physicians and
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older patients weight benefit and harm in shared deci-
sion-making. Moreover, there is an urgent need to
implement multimorbidity guidelines [34] as an
important supplement to the existing single-disease
guidelines, allowing physicians to adjust drug use to
the individual needs of older patients [6].
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